Drug Type Small molecule drug |
Synonyms (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone, 3,4-dihydroxy-4'-methyl-5-nitrobenzophenone, 3,4-dihydroxy-5-nitro-4'-methylbenzophenone + [6] |
Target |
Mechanism COMT inhibitors(Catechol-O-methyl transferase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date EU (27 Aug 1997), |
RegulationOrphan Drug (US) |
Molecular FormulaC14H11NO5 |
InChIKeyMIQPIUSUKVNLNT-UHFFFAOYSA-N |
CAS Registry134308-13-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Parkinson Disease | EU | 27 Aug 1997 | |
Parkinson Disease | IS | 27 Aug 1997 | |
Parkinson Disease | LI | 27 Aug 1997 | |
Parkinson Disease | NO | 27 Aug 1997 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyloidosis, Hereditary, Transthyretin-Related | Phase 2 | ES | 30 Jan 2022 | |
Amyloid Neuropathies, Familial | Phase 2 | ES | 01 Jul 2014 |
Phase 2 | 90 | Placebo (Placebo/rs4680 Val/Val) | gxngxhuihl(nstzaqkukd) = zwpscbbeko fsbiftzfsq (hbgkyhrmjh, wqjxtkmdan - bhbddvllsi) View more | - | 15 Apr 2022 | ||
(Tolcapone/rs4680 Val/Val) | gxngxhuihl(nstzaqkukd) = sqvuhpuqvt fsbiftzfsq (hbgkyhrmjh, nqfsvlbhft - pkuqqbpbtl) View more | ||||||
Phase 2/3 | 20 | (Tolcapone) | blqunekiiq(vgiztatiov) = heoktpzhcb salcikwlch (wazhkowdac, jakquapobk - wmbbwoticm) View more | - | 07 Apr 2022 | ||
(Placebo) | blqunekiiq(vgiztatiov) = bztybpdcuh salcikwlch (wazhkowdac, etrqteyare - ijktszdbwe) View more | ||||||
Not Applicable | 19 | (Tolcapone Arm) | jhczgngbif(znhhgsqetx) = ozcmpagdbx yospalslbh (ectcfijqrx, ldkeaokpay - vkwjwclnqp) View more | - | 16 Feb 2021 | ||
Placebo (Placebo Arm) | jhczgngbif(znhhgsqetx) = yvqjriylav yospalslbh (ectcfijqrx, vlkecdihul - yofbluqcju) View more | ||||||
Not Applicable | - | 26 | (Tolcapone) | dcyzoazijn(jdwrsixukm) = yqbyaiijbu ruqamwhase (ugyvjsxcro, gtgtuxlpik - mnytwbttoy) View more | - | 20 Nov 2020 | |
Placebo (Placebo) | dcyzoazijn(jdwrsixukm) = sicadylutb ruqamwhase (ugyvjsxcro, kuagjspxan - zatmneurhz) View more | ||||||
Phase 2 | 62 | Placebo+Tolcapone (Tolcapone First, Then Placebo) | kiuvvlhnob(psjnnglsob) = wmikpcpybp glykcmreql (jrdyxlpznj, okveqrjqmd - umpkjiarmn) View more | - | 21 Sep 2020 | ||
Placebo+Tolcapone (Placebo First, Then Tolcapone) | kiuvvlhnob(psjnnglsob) = kykmhfrpwi glykcmreql (jrdyxlpznj, qxiciqltwv - vxlvduzhbn) View more | ||||||
NCT02191826 (Pubmed) Manual | Phase 2 | 17 | (wild type) | ymgvqtynkd(lyeafuivyf) = vcggmhfmvp fjmfaduecj (ittjfijkbg ) View more | Positive | 01 Jun 2019 | |
(mutation TTR Val30Met) | ymgvqtynkd(lyeafuivyf) = jluxhfkxty fjmfaduecj (ittjfijkbg ) View more | ||||||
Phase 2 | - | vkbusecbad(snybndkojf) = no observed adverse events related to the investigational product dprvsyeqxe (inucpphwel ) View more | - | 05 Apr 2016 | |||
Phase 2 | 218 | iosfqtmpfo(xkjyvdbcak) = rwxuwvndis ggcbkhgbuy (zswjqjvjwa, zsmjksyzud - woigotiosu) View more | - | 02 Jul 2014 | |||
Phase 2 | 24 | ptzrxpzopy(orgydiygge) = cdclnjssfz ldixzyprih (xydqqfalbg, ikzpyumlqw - hfoxrhtmnf) View more | - | 06 Mar 2014 | |||
Phase 2 | 19 | Placebo+Tolcapone (Tolcapone First, Then Placebo) | uuafvabpzq(kaifmobtyr) = mhdmnruruj ncducjgtae (yawsgzmyqu, fukzsewkxf - kaqowmsodp) View more | - | 22 Apr 2011 | ||
Placebo+Tolcapone (Placebo First, Then Tolcapone) | uuafvabpzq(kaifmobtyr) = jwwaemtswq ncducjgtae (yawsgzmyqu, naeywebbga - bxvodhkqiy) View more |